len schleifer, ceo for regeneron. stay with cramer. >>> coming up -- walgreens is working its way from pharmacy focused retailer to the larger $2.6 trillion health care market. you probably stopped at the corner store. is it time to invest in it? find out in cramer's exclusive. >>> plus, future forecast. biotech alkermes updated the drug pipeline last week, causing the stock to rise on the 10%. is the news fully factored into the share price or could its long term plan mean the rally's just begun? cramer talks to the ceo. all coming up on "mad money." [ male announcer ] this is the story of the dusty basement at 1406 35th street the old dining table at 25th and hoffman. ...and the little room above the strip mall off roble avenue. ♪ this magic moment it is the story of where every great idea begins. and of those who believed they had the power to do more. dell is honored to be part of some of the world's great stories. that began much the same way ours did. in a little dorm room -- 2713. ♪ this magic moment ♪ >>> tomo

remember that's how regeneron started out, went to $274. and i can't tell you how many people at my book signing last night in new jersey thanked me for sirius, sprint, rite aid. and, hey, try to find your way to the costco tomorrow at noon, get a signed copy of "get rich carefully." can intercept still be bought? i said last night you should take half your capital out of it if you own it, play with the house's money. i can understand how a growth company like merck or ely lilly might make a tender offer. back when they had no earnings or sales to speak of. these growth challenge dinosaurs could do worse than paying $11 billion for the $8 billion company if the drug turns out as miraculous as it sounds. gilead's stock went up. these stocks, i'm telling you, if their ceos picked up a phone and bought intercept this weekend, their stocks would go up, too. not down, but up. lots of people think the official kickoff for earnings season is not alcoa. it's reported yesterday. but actually with the banks. i think it really does start when jpmorgan

remember that's how regeneron started out, $5 stock went to $274. and i can't tell you how many people at my book signing last night in new jersey thanked me for sirius, sprint, rite aid. and, hey, try to find your way to the costco tomorrow at noon, get a signed copy of "get rich carefully." can intercept still be bought? i said last night you should take half your capital out of it if you own it, play with the house's money. i can understand how a growth strapped company mick merck or ely lilly might make a tender offer for intercept. just like pharma cpt. back when they had no earnings or sales to speak of. these growth challenge dinosaurs could do worse than paying $11 billion for the $8 billion company if the drug turns out as miraculous as it sounds. gilead's stock went up. these stocks, i'm telling you, lille and merck, if their ceos picked up a phone and bought intercept this weekend, their stocks would go up, too. not down, but up. lots of people think the official kickoff for earnings season is not alcoa. it's reported yesterday. but actua

leading the index higher, regeneron, which will report about $1.4 billion in u.s. sales of its high profile eye drug for the year. its ceo saying there's lots of room for future growth. also intuitive surgical which issued fiscal year guidance above street estimates and jabil circuit which was added to the buy list. tyler? >>> france's president francois hollande facing le media today amid a firestorm surrounding his private life, claims of an affair with an actress. michelle? >> that's good. the french president says quote, private matters should remain private to a crowd of some 600 french and foreign journalists who gathered at the palace in paris, which just wrapped up five minutes ago. those comments came during a more than two and a half hour news conference which was supposed to be about hollande's new economic plan for france. in fact, the french president talked about cutting taxes and cutting red tape. big news in and of itself for the socialist president. that, he did for the first 50 minutes of the event but when the q & a started, the very first report

regeneron ended on a gain of 12%. >>> biotech firms often find themselves at the mercy of regulators and their tough approval process before new medications can reach the market. but the food and drug administration has now set up a separate system to fast track the approval of priority drugs in the pipeline, benefitting the companies along with the potential patients. morgan brennan has more. >> reporter: the u.s. food and drug administration has special high priority pipelines for drugs in development that could be potentially ground-breaking. they are geared towards getting patients promising treatments faster and the approval rates can be higher for these fast track drugs. analysts say these high priority pipe lines have become increasingly important to investors, especially those looking to find the next big biotech breakout. >> for larger companies obviously it's not quite as meaningful. but for smaller companies, this becomes more and more important. it gives you an early read of fda's impression of the drug which is very helpful for investors. >> reporter: perhaps no designat

but equally we want -- we don't want to particularize, as the ceo of regeneron likes to say we don'tto contribute what they can do best and grow businesses. but you know, often we want to control in this industry and own and the people who are inside these companies, really driving the science, are not really happy with that arrangement and tend to leave. this is a way of sanofi participating in very cutting-edge science. it's right in the sweet spot of where genzyme is. genzyme is the leading rare disease company worldwide. i think both of our businesses can grow out of this relationship. >> i have two questions for you first is the degree to which you feel personal pressure to be seen to be doing something because of course genzyme's new multiple sclerosis drug rejected by u.s. authorities last month. the second question, whether you can flesh out what new technology is in the acquisition today, the idea that you can provent genes from being designated proteins. >> so, i mean, if you look at genzyme, it's our second biggest growth driver after diabetes. we have been able to success

pdl pharma, it's not biogen, regeneron, celgene, gilead. it's a nice spec.e when i recommended. i'm not keen on tobacco. at&t and verizon. we can't have both of these. that's not going to work. i know you want some yield and you feel like yield should be the thing here. i'm going to send you to another stock that was downgraded today. clorox. and that, ladies and gentlemen, is another round of am i diversified. >>> after the close one of my bankable 21 ceos from macy's reported a number that was really good and sent the stock up after hours. i like macy's. just for you right here on "mad money." i'm jim cramer and i will see you tomorrow! [ helicopter blades whirring ] [ sea gulls squawking ] [ indistinct shouting ]

and walgreen's and regeneron, top of the hour with jim. [ male announcer ] start the engine...s of a transmission connected to more standard horsepower than its german competitors. and that is the moment that driving the lexus gs will shift your perception. this is the pursuit of perfection. see, i knew testosterone could affect sex drive, but not energy or even my mood. that's when i talked with my doctor. he gave me some blood tests... showed it was low t. that's it. it was a number. [ male announcer ] today, men with low t have androgel 1.62% testosterone gel. the #1 prescribed topical testosterone replacement therapy increases testosterone when used daily. women and children should avoid contact with application sites. discontinue androgel and call your doctor if you see unexpected signs of early puberty in a child, or signs in a woman, which may include changes in body hair or a large increase in acne, possibly due to accidental exposure. men with breast cancer or who have or might have prostate cancer, and women who are or may become pregnant or are breast-feeding, should

regeneron, biotech, auto parts, real estate investment trust.ospace. aerospace, drug, supermarket, bingo, totally diversified. let's go to ollie in minnesota. >> caller: booyah, jim, from minnesota. >> fantastic to have you. >> caller: my five stocks are gold, phillip morris pm, standard pacific, energy transfer partners, and kbr incorporated. am i diversified, jim? >> let's take a look. phillip morris, that's the international version of altria. i'm questioning the growth rate there by the way. i think it's slowing down. standard pacific, large home builder, energy transfer, they could make a comeback, the gold, kbr is infrastructure play, engineering construction. gold, tobacco and housing, again, i say fabulous! now let's go to doug in california. doug? >> caller: jim, i'm looking at five stocks here. yum brands, gilead, discover, linn energy and boeing. >> i like this portfolio. gilead is red hot. one of the four horsemen of big pharma apocalypse. discover is a credit card company, yum which is the turnaround in china, i think you must be in

i'm telling you about the four horse men that embody this trend, that celgene, regeneron, we've got to give these a rest. but these four stocks all have magnificent years in 2013, terrific runs this january, until the market fell off a cliff last week, too early to buy. the last three sessions, though, practically seen the four horsemen sent to the glue factory. nothing's changed for the underlying companies as much as we want to think they have. after the current squall of selling, i bet the stocks bounce back. the hideous decline we're seeing is creating some pretty fabulous entry points as they go down. you know i'm a fan of the four horsemen and you have my blessing to buy anything of them in the weakness right here. don't buy all at once. but tonight, i want you to focus on a smaller pair of biotechs that were among the best performers in the space for 2013 because with the current selloff, you're finally, finally getting a chance to buy these two names prices a lot more reasonable than they've been. first break in the action they've had, isis pharmaceuticals and jazz. these two c

couple of picks here, goldman says amgen and regeneron and deutsche bank says biogen, which actuallyted earnings and that stock is a big nasdaq winner. >>> sex sells pretty much anything, including watches, it turns out. robert frank? >> indeed. turns out there is a secret world of wealthy collectors of erotic watches, watches filled with diamonds, gold and some very interesting movements. we will give you a peek after the break. [ tires screech ] [ car alarm chirps ] ♪ [ male announcer ] we don't just certify our pre-owned vehicles. we inspect, analyze, and recondition each one, until it's nothing short of a genuine certified pre-owned mercedes-benz for the next new owner. [ car alarm chirps ] hurry in to your authorized mercedes-benz dealer for 1.99% financing during our certified pre-owned sales event through february 28th. >>> watch the dow there, folks. watch the dow, down 145 ahead of the fed. new episode of "secret lives of the super rich" at 9:00 p.m. eastern on cnbc. robert frank here with a sneak peek. erotic watches. >> peek is right. tonight we will show you some obscene

. >> you have an adjusting relationship with regeneron. you have a cardiovascular drug.own 15-15% of the co mpany. >> that would be a good way to screw it up. there is just a good culture that is needed at every stage of research. there's a stage where you have to be rigorous and you need deep competencies in certain areas. there is a spot where you need to be a little bit more risk-taking and think about new things. on has a fabulous platform in antibodies. they also have something better. they have replicated the human immune system inside a mouse. we can rapidly validate targets. we also have an option to enter into products coming along. we codevelop them. we bring something, they bring something. the dream of their people is not to work for big pharma. we get the best of both worlds. you can bring so much of her understanding. r&d want to move from an company to a commercial company. they acquired a suite of patterns from mark. they are doing research in the same space. if we had bought it, we would have screwed it up to. nothing against merck. you need to keep the

let's number two is regeneron. stock rating to outperform because of valuations.e drugmakers pipeline value will take longer to realize profits. >> all right, let's get to our number was stock of the day. it happens to be bank of america. climbing 2%, the highest since 2010. one reason for the jump in earnings is that it is reducing the number -- the amount of money is paying due to the decrease in mortgages. [bellringing] seaworld ringing the bell there. i have been under a lot of fire there after a documentary that we will talk about. nasdaq in the green there. you can see .6% gain. more economic optimism, you could say, as a result of the beige book. >> it came from the fed in the form of the beige book. it also came in the form of producer prices, which are up about .4%. and you will want a little bit of inflation, it suggests there is growth. >> financials ending up 1.2%. telecom the best on the day with 1.5% gain there. >> look like -- looks like it might be a record for the s&p. >> it's a record for the s&p, but here's the funny thing -- it is closing flat

regeneron reporting u.s. sales of its i-drug will hit $1.4 billion for the year. its ceo is saying there's plenty of room to grow. he's going to be on "mad money" with jim cramer at 6:00 p.m. and 11:00 p.m. eastern. and a strong day for intuitive surgical as well. the company is delivering fourth quarter revenue guidance above wall street estimates. on the down side we have boeing. this after battery problems resurfaced on the 787 dreamliner. it released some gas from the battery. it was discovered during a scheduled maintenance exam hours before the japan airlines flight was to take off, and a tough day for game stop. this after the video game retailer forecast fourth quarter profits below street expectations and we end with intercept pharmaceuticals dropping another 32% after gaining more than 500% last week. bill, back over to you. >> what a round turn that has been. >> incredible. >> straight up, straight down. thanks, dom. elsewhere, there's an important development in that big nfl concussion settlement that was reached recently. a judge now says not so fast.